Know What's Happening in Pharma

HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVO

Hims & Hers reported Q4 results after the bell, with mixed performance, drawing investor focus on its GLP‑1 program and forward guidance. The company posted EPS of $0.08, double expectations, but revenue of $617 million fell short of the $619 million forecast. For Q1, guidance of $600‑$625 million disappointed analysts who had modeled $654 million, reflecting pressure from GLP‑1 price erosion and regulatory scrutiny. Analysts Christine Short highlighted a 30%+ growth in the core sexual‑health and dermatology segments, noting that only a small fraction of the 2.5 million subscribers use GLP‑1. Brian Tanquilut reiterated a “hold” rating, citing the Novo Nordisk patent lawsuit and the fading GLP‑1 halo as near‑term valuation caps, while emphasizing the company’s shift toward a holistic, personalized‑medicine model. The market’s initial sell‑off has softened as investors reassess the pivot away from GLP‑1 dependence. However, ongoing legal liabilities and uncertain GLP‑1 pricing dynamics keep the stock’s upside limited, making execution of the broader telehealth strategy critical for long‑term growth.